Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Study sponsor: Actinium Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-02Estimated
Enrollment · participants306Estimated
Source updated2025-09-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.